Impact of Plerixafor Use at Different Peripheral Blood CD34+ Cell Thresholds on Autologous Stem Cell Collection in Patients with Multiple Myeloma

ABSTRACT Patients with multiple myeloma planning for autologous stem cell transplant must undergo autologous stem cell mobilization, however many unfortunately do not obtain an adequate collection yield. Despite the availability of plerixafor, widespread and uniform use is limited by its cost, and consequently, many institutions have adopted various risk-adapted algorithms. We report our mobilization experience as we have modified our plerixafor algorithm to a more liberal one, expecting greater collection efficiency and mobilization success with higher plerixafor use. A total of 344 mobilization attempts were analyzed, occurring over three time periods and utilizing three different peripheral blood CD34+ cell counts to guide plerixafor use: CD34+